Switch to:
Also traded in: Germany, Mexico, Spain, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.22
GRFS's Cash to Debt is ranked lower than
93% of the 941 Companies
in the Global Biotechnology industry.

( Industry Median: 45.46 vs. GRFS: 0.22 )
Ranked among companies with meaningful Cash to Debt only.
GRFS' s Cash to Debt Range Over the Past 10 Years
Min: 0.07  Med: 0.23 Max: No Debt
Current: 0.22
Equity to Asset 0.36
GRFS's Equity to Asset is ranked lower than
79% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. GRFS: 0.36 )
Ranked among companies with meaningful Equity to Asset only.
GRFS' s Equity to Asset Range Over the Past 10 Years
Min: 0.28  Med: 0.33 Max: 0.37
Current: 0.36
0.28
0.37
Interest Coverage 3.94
GRFS's Interest Coverage is ranked lower than
89% of the 369 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GRFS: 3.94 )
Ranked among companies with meaningful Interest Coverage only.
GRFS' s Interest Coverage Range Over the Past 10 Years
Min: 1.39  Med: 4.09 Max: 18.28
Current: 3.94
1.39
18.28
F-Score: 6
Z-Score: 2.35
M-Score: -2.77
WACC vs ROIC
5.56%
12.28%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 24.23
GRFS's Operating margin (%) is ranked higher than
88% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -75.67 vs. GRFS: 24.23 )
Ranked among companies with meaningful Operating margin (%) only.
GRFS' s Operating margin (%) Range Over the Past 10 Years
Min: 15.53  Med: 24.81 Max: 26.85
Current: 24.23
15.53
26.85
Net-margin (%) 13.27
GRFS's Net-margin (%) is ranked higher than
83% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -76.14 vs. GRFS: 13.27 )
Ranked among companies with meaningful Net-margin (%) only.
GRFS' s Net-margin (%) Range Over the Past 10 Years
Min: 2.8  Med: 12.60 Max: 16.2
Current: 13.27
2.8
16.2
ROE (%) 16.54
GRFS's ROE (%) is ranked higher than
90% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -32.22 vs. GRFS: 16.54 )
Ranked among companies with meaningful ROE (%) only.
GRFS' s ROE (%) Range Over the Past 10 Years
Min: 4.27  Med: 17.87 Max: 26.13
Current: 16.54
4.27
26.13
ROA (%) 5.69
GRFS's ROA (%) is ranked higher than
85% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. GRFS: 5.69 )
Ranked among companies with meaningful ROA (%) only.
GRFS' s ROA (%) Range Over the Past 10 Years
Min: 1.34  Med: 6.03 Max: 8.93
Current: 5.69
1.34
8.93
ROC (Joel Greenblatt) (%) 34.42
GRFS's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. GRFS: 34.42 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GRFS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 18.86  Med: 36.06 Max: 41.34
Current: 34.42
18.86
41.34
Revenue Growth (3Y)(%) 14.50
GRFS's Revenue Growth (3Y)(%) is ranked higher than
68% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. GRFS: 14.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GRFS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 14.5  Med: 20.40 Max: 26.5
Current: 14.5
14.5
26.5
EBITDA Growth (3Y)(%) 12.70
GRFS's EBITDA Growth (3Y)(%) is ranked higher than
69% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. GRFS: 12.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
GRFS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 12.7  Med: 29.10 Max: 38.2
Current: 12.7
12.7
38.2
EPS Growth (3Y)(%) 27.40
GRFS's EPS Growth (3Y)(%) is ranked higher than
82% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -5.20 vs. GRFS: 27.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GRFS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 7  Med: 28.30 Max: 96.1
Current: 27.4
7
96.1
» GRFS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

GRFS Guru Trades in Q2 2015

Jim Simons 202,702 sh (+163.24%)
Mario Gabelli 30,200 sh (+8.37%)
John Paulson 17,821,040 sh (+0.11%)
Ron Baron 33,000 sh (-12.70%)
» More
Q3 2015

GRFS Guru Trades in Q3 2015

Steven Cohen 84,777 sh (New)
Ron Baron 35,000 sh (+6.06%)
John Paulson 17,729,140 sh (-0.52%)
Mario Gabelli 26,200 sh (-13.25%)
Jim Simons 8,302 sh (-95.90%)
» More
Q4 2015

GRFS Guru Trades in Q4 2015

Mario Gabelli 28,700 sh (+119.08%)
Ron Baron 35,000 sh (+100.00%)
John Paulson 12,398,140 sh (+39.86%)
Steven Cohen Sold Out
Jim Simons Sold Out
» More
Q1 2016

GRFS Guru Trades in Q1 2016

Jim Simons 188,304 sh (New)
Ron Baron 75,000 sh (+7.14%)
Mario Gabelli 57,400 sh (unchged)
John Paulson 17,533,764 sh (-29.29%)
» More
» Details

Insider Trades

Latest Guru Trades with GRFS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:GMXAY, NAS:MDVN, NAS:BMRN, NAS:JAZZ, OTCPK:NVZMY, OTCPK:UCBJF, NAS:INCY, NAS:ALKS, NAS:DYAX, NAS:SGEN, NAS:OPK, OTCPK:ALIOY, OTCPK:SBMFF, NAS:ALNY, NAS:UTHR, NAS:ANAC, NAS:JUNO, NAS:TECH, OTCPK:BTGGF, NAS:ACAD » details
Traded in other countries:G0FB.Germany, GRFPN.Mexico, GRF.P.Spain, 0RDU.UK, GIKLY.USA,
Grifols SA is a specialty biopharmaceutical company that develops, manufactures and distributes a broad range of plasma derivative products. It operates in four business divisions: Bioscience, Diagnostic, Hospital and Raw Materials and Others.

Grifols SA Was incorporated on June 22, 1987. It is a specialty biopharmaceutical company that develops, manufactures and distributes a broad range of plasma derivative products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. The Company operates in four business divisions: Bioscience, Diagnostic, Hospital and Raw Materials. The Bioscience division includes activities relating to the manufacture of plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation and purification of plasma, and the sale and distribution of end products. The main plasma products it manufactures are IVIG, Factor VIII, A1PI and albumin. It also manufactures intramuscular immunoglobulins, ATIII, Factor IX and plasma thromboplastin component, or PTC. The Diagnostic division focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, including analytical instruments and reagents for diagnostics, as well as blood bank products. The Company concentrates its Diagnostic business in immunohematology and hemostasis product lines. The Diagnostic division's main customers are blood donation centers, clinical analysis laboratories and hospital immunohematology services. The Raw Material division provides raw materials for its intravenous therapy products like plastic and glass bottles, which the company purchases from various European suppliers. The Hospital division manufactures and installs products used by and in hospitals, such as parenteral solutions and enteral and parenteral nutritional fluids, which are sold almost exclusively in Spain and Portugal. It also includes products that the company does not manufacture. The Company operates in Latin America, in countries such as Mexico, Colombia, Argentina, Chile and Brazil. It sells Bioscience, Diagnostic and Hospital products to hospitals and clinics, GPOs, governments and other distributors globally. The Company's operations are subject to government authorities in the United States, at the federal, state and local level, and in other countries in which it operates.

Ratios

vs
industry
vs
history
P/E(ttm) 24.47
GRFS's P/E(ttm) is ranked higher than
60% of the 230 Companies
in the Global Biotechnology industry.

( Industry Median: 29.12 vs. GRFS: 24.47 )
Ranked among companies with meaningful P/E(ttm) only.
GRFS' s P/E(ttm) Range Over the Past 10 Years
Min: 22.82  Med: 34.23 Max: 96.2
Current: 24.47
22.82
96.2
Forward P/E 15.11
GRFS's Forward P/E is ranked lower than
51% of the 65 Companies
in the Global Biotechnology industry.

( Industry Median: 20.62 vs. GRFS: 15.11 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 24.47
GRFS's PE(NRI) is ranked higher than
60% of the 230 Companies
in the Global Biotechnology industry.

( Industry Median: 28.93 vs. GRFS: 24.47 )
Ranked among companies with meaningful PE(NRI) only.
GRFS' s PE(NRI) Range Over the Past 10 Years
Min: 22.65  Med: 33.53 Max: 93.37
Current: 24.47
22.65
93.37
Price/Owner Earnings (ttm) 32.49
GRFS's Price/Owner Earnings (ttm) is ranked higher than
50% of the 131 Companies
in the Global Biotechnology industry.

( Industry Median: 32.52 vs. GRFS: 32.49 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
GRFS' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 18.88  Med: 31.53 Max: 37.52
Current: 32.49
18.88
37.52
P/B 3.89
GRFS's P/B is ranked lower than
57% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. GRFS: 3.89 )
Ranked among companies with meaningful P/B only.
GRFS' s P/B Range Over the Past 10 Years
Min: 2.32  Med: 4.34 Max: 6.76
Current: 3.89
2.32
6.76
P/S 3.25
GRFS's P/S is ranked higher than
78% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 10.08 vs. GRFS: 3.25 )
Ranked among companies with meaningful P/S only.
GRFS' s P/S Range Over the Past 10 Years
Min: 1.86  Med: 3.49 Max: 5.09
Current: 3.25
1.86
5.09
PFCF 26.33
GRFS's PFCF is ranked higher than
51% of the 126 Companies
in the Global Biotechnology industry.

( Industry Median: 26.54 vs. GRFS: 26.33 )
Ranked among companies with meaningful PFCF only.
GRFS' s PFCF Range Over the Past 10 Years
Min: 15.52  Med: 28.69 Max: 86.82
Current: 26.33
15.52
86.82
POCF 16.86
GRFS's POCF is ranked higher than
62% of the 183 Companies
in the Global Biotechnology industry.

( Industry Median: 22.98 vs. GRFS: 16.86 )
Ranked among companies with meaningful POCF only.
GRFS' s POCF Range Over the Past 10 Years
Min: 10.97  Med: 17.98 Max: 1270
Current: 16.86
10.97
1270
EV-to-EBIT 17.54
GRFS's EV-to-EBIT is ranked higher than
58% of the 248 Companies
in the Global Biotechnology industry.

( Industry Median: 22.57 vs. GRFS: 17.54 )
Ranked among companies with meaningful EV-to-EBIT only.
GRFS' s EV-to-EBIT Range Over the Past 10 Years
Min: 12.6  Med: 19.70 Max: 43.3
Current: 17.54
12.6
43.3
EV-to-EBITDA 14.50
GRFS's EV-to-EBITDA is ranked higher than
58% of the 273 Companies
in the Global Biotechnology industry.

( Industry Median: 19.06 vs. GRFS: 14.50 )
Ranked among companies with meaningful EV-to-EBITDA only.
GRFS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.3  Med: 15.95 Max: 32.9
Current: 14.5
10.3
32.9
PEG 0.89
GRFS's PEG is ranked higher than
80% of the 92 Companies
in the Global Biotechnology industry.

( Industry Median: 2.14 vs. GRFS: 0.89 )
Ranked among companies with meaningful PEG only.
GRFS' s PEG Range Over the Past 10 Years
Min: 0.66  Med: 0.82 Max: 0.9
Current: 0.89
0.66
0.9
Current Ratio 3.31
GRFS's Current Ratio is ranked lower than
60% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. GRFS: 3.31 )
Ranked among companies with meaningful Current Ratio only.
GRFS' s Current Ratio Range Over the Past 10 Years
Min: 2.19  Med: 2.93 Max: 3.31
Current: 3.31
2.19
3.31
Quick Ratio 1.69
GRFS's Quick Ratio is ranked lower than
75% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. GRFS: 1.69 )
Ranked among companies with meaningful Quick Ratio only.
GRFS' s Quick Ratio Range Over the Past 10 Years
Min: 1.15  Med: 1.52 Max: 1.88
Current: 1.69
1.15
1.88
Days Inventory 249.84
GRFS's Days Inventory is ranked lower than
79% of the 449 Companies
in the Global Biotechnology industry.

( Industry Median: 128.00 vs. GRFS: 249.84 )
Ranked among companies with meaningful Days Inventory only.
GRFS' s Days Inventory Range Over the Past 10 Years
Min: 235.92  Med: 286.75 Max: 1027.84
Current: 249.84
235.92
1027.84
Days Sales Outstanding 34.75
GRFS's Days Sales Outstanding is ranked higher than
72% of the 611 Companies
in the Global Biotechnology industry.

( Industry Median: 63.07 vs. GRFS: 34.75 )
Ranked among companies with meaningful Days Sales Outstanding only.
GRFS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 33.61  Med: 54.47 Max: 83.07
Current: 34.75
33.61
83.07
Days Payable 68.29
GRFS's Days Payable is ranked higher than
56% of the 450 Companies
in the Global Biotechnology industry.

( Industry Median: 59.87 vs. GRFS: 68.29 )
Ranked among companies with meaningful Days Payable only.
GRFS' s Days Payable Range Over the Past 10 Years
Min: 64.56  Med: 96.89 Max: 257.68
Current: 68.29
64.56
257.68

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.27
GRFS's Dividend Yield is ranked higher than
77% of the 219 Companies
in the Global Biotechnology industry.

( Industry Median: 1.29 vs. GRFS: 2.27 )
Ranked among companies with meaningful Dividend Yield only.
GRFS' s Dividend Yield Range Over the Past 10 Years
Min: 0.38  Med: 1.01 Max: 2.36
Current: 2.27
0.38
2.36
Dividend Payout 0.42
GRFS's Dividend Payout is ranked lower than
64% of the 115 Companies
in the Global Biotechnology industry.

( Industry Median: 0.31 vs. GRFS: 0.42 )
Ranked among companies with meaningful Dividend Payout only.
GRFS' s Dividend Payout Range Over the Past 10 Years
Min: 0.53  Med: 0.71 Max: 0.92
Current: 0.42
0.53
0.92
Forward Dividend Yield 3.47
GRFS's Forward Dividend Yield is ranked higher than
86% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 1.29 vs. GRFS: 3.47 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 2.27
GRFS's Yield on cost (5-Year) is ranked higher than
67% of the 254 Companies
in the Global Biotechnology industry.

( Industry Median: 1.46 vs. GRFS: 2.27 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
GRFS' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.38  Med: 1.01 Max: 2.36
Current: 2.27
0.38
2.36
3-Year Average Share Buyback Ratio -1.50
GRFS's 3-Year Average Share Buyback Ratio is ranked higher than
86% of the 550 Companies
in the Global Biotechnology industry.

( Industry Median: -11.40 vs. GRFS: -1.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GRFS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17.3  Med: -8.40 Max: -1.1
Current: -1.5
-17.3
-1.1

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.72
GRFS's Price/Projected FCF is ranked higher than
58% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 3.31 vs. GRFS: 2.72 )
Ranked among companies with meaningful Price/Projected FCF only.
GRFS' s Price/Projected FCF Range Over the Past 10 Years
Min: 2.83  Med: 2.96 Max: 3.09
Current: 2.72
2.83
3.09
Price/Median PS Value 0.93
GRFS's Price/Median PS Value is ranked lower than
52% of the 633 Companies
in the Global Biotechnology industry.

( Industry Median: 0.91 vs. GRFS: 0.93 )
Ranked among companies with meaningful Price/Median PS Value only.
GRFS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.57  Med: 0.98 Max: 1.37
Current: 0.93
0.57
1.37
Price/Peter Lynch Fair Value 0.98
GRFS's Price/Peter Lynch Fair Value is ranked higher than
78% of the 58 Companies
in the Global Biotechnology industry.

( Industry Median: 1.79 vs. GRFS: 0.98 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
GRFS' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.95  Med: 0.99 Max: 1.02
Current: 0.98
0.95
1.02
Earnings Yield (Greenblatt) (%) 5.69
GRFS's Earnings Yield (Greenblatt) (%) is ranked higher than
89% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. GRFS: 5.69 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GRFS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.3  Med: 5.10 Max: 7.9
Current: 5.69
2.3
7.9
Forward Rate of Return (Yacktman) (%) 31.76
GRFS's Forward Rate of Return (Yacktman) (%) is ranked higher than
79% of the 114 Companies
in the Global Biotechnology industry.

( Industry Median: 14.46 vs. GRFS: 31.76 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
GRFS' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 31.6  Med: 31.80 Max: 38.3
Current: 31.76
31.6
38.3

More Statistics

Revenue (TTM) (Mil) $4,429
EPS (TTM) $ 0.86
Beta1.06
Short Percentage of Float0.25%
52-Week Range $14.07 - 18.04
Shares Outstanding (Mil)683.52

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 4,377 4,575
EPS ($) 0.96 1.08
EPS w/o NRI ($) 0.96 1.08
EPS Growth Rate
(3Y to 5Y Estimate)
7.02%
» More Articles for GRFS

Headlines

Articles On GuruFocus.com
John Paulson Raises Stake in Valeant, Teva Pharmaceutical Mar 18 2016 
Gold-Focused Guru John Paulson Reports First Quarter Holdings May 22 2014 
Is Grifols Being Overlooked? Mar 19 2014 
John Paulson's Top Five Holdings Nov 20 2013 
John Paulson's Top Five Holdings Sep 12 2013 
Baron Funds Comments on Grifols SA Aug 30 2012 
Friday Value Overview Aug 19 2011 

More From Other Websites
Award Winner of the 2016 SPIN Awards Program Jun 29 2016
Grifols SA : GRFS-US: Dividend Analysis : June 06th, 2016 : By the numbers : June 23, 2016 Jun 22 2016
Grifols SA :GRFS-US: Earnings Analysis: Q1, 2016 By the Numbers : June 22, 2016 Jun 22 2016
FDA Approves Use of the Procleix Zika Virus Assay from Hologic and Grifols to Screen the U.S. Blood... Jun 21 2016
Zika Blood Screening Test From Hologic, Grifols Gets FDA Nod Jun 20 2016
Hologic And Grifols Get FDA Approval For Procleix Zika Virus Assay Jun 20 2016
FDA Approves Use of the Procleix Zika Virus Assay from Hologic and Grifols to Screen the U.S. Blood... Jun 20 2016
Analyzing IBB’s Moving Averages Jun 16 2016
Grifols confirms that it has voluntarily signed the EFPIA Code of Conduct Jun 16 2016
Grifols Maintains Its Dividend Payout at 40% Jun 01 2016
Singulex announces a $50 million investment by Grifols for a 20% stake in the company May 31 2016
Grifols allocates EUR 213 million to dividends and maintains pay-out at 40% of consolidated net... May 27 2016
Grifols allocates EUR 213 million to dividends and maintains pay-out at 40% of consolidated net... May 27 2016
5 Big Dividend Stocks Billionaire John Paulson Loves May 23 2016
Grifols' revenues increase by +5.6% to Euros 959 million, driven by growth of +10.9% for the... May 05 2016
Grifols' revenues increase by +5.6% to Euros 959 million, driven by growth of +10.9% for the... May 05 2016
ETF’s with exposure to Grifols SA : May 4, 2016 May 04 2016
The Catalan Down's Syndrome Foundation and Grifols are working together to promote research Apr 18 2016
GRIFOLS SA Financials Apr 08 2016
ETF’s with exposure to Grifols SA : April 6, 2016 Apr 06 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)